Back to Search Start Over

Clinical, molecular, physiologic, and therapeutic feature of patients with CHRNA4 and CHRNB2 deficiency: A systematic review.

Authors :
Jalaiei A
Asadi MR
Daneshmandpour Y
Rezazadeh M
Ghafouri-Fard S
Source :
Journal of neurochemistry [J Neurochem] 2025 Jan; Vol. 169 (1), pp. e16200. Date of Electronic Publication: 2024 Aug 28.
Publication Year :
2025

Abstract

The α4β2 nAChRs are crucial ion channels that control neurotransmitter release and play a role in various physiologic and pathologic processes. CHRNA4 encodes the α4-nAChRs, while CHRNB2 encodes the β2-nAChRs. Recent studies have found different variants of α4β2-nAChRs in individuals with conditions such as AD, ADHD, ALS, PD, and brain abnormalities. We conducted a scoping review following a six-stage methodology structure and adhering to PRISMA guidelines. We systematically reviewed articles using relevant keywords up to October 2, 2023. In this summary, we cover the clinical symptoms reported, the genes and protein structure of CHRNA4 and CHRNB2, mutations in these genes, inheritance patterns, the functional impact of mutations and polymorphisms in CHRNA4 and CHRNB2, and the epidemiology of these diseases. Recent research indicates that nAChRs may play a significant role in neurodegenerative disorders, possibly impacting neuronal function through yet undiscovered regulatory pathways. Studying how nAChRs interact with disease-related aggregates in neurodegenerative conditions may lead to new treatment options for these disorders.<br /> (© 2024 International Society for Neurochemistry.)

Details

Language :
English
ISSN :
1471-4159
Volume :
169
Issue :
1
Database :
MEDLINE
Journal :
Journal of neurochemistry
Publication Type :
Academic Journal
Accession number :
39193833
Full Text :
https://doi.org/10.1111/jnc.16200